This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Ebola virus	Ebola glycoprotein GP1; Ebola glycoprotein GP2	<p>Primate studies suggest combining anti-Ebola antibodies plus interferon-α (IFNA; IFN-α) could help treat Ebola virus. In cynomolgus and rhesus macaques, ZMAb—a combination of three murine antibodies that target GP1 and GP2—plus DEF201, an adenoviral vector-delivered IFN-α, protected 75%–100% of animals when given 3 days after infection. In cynomolgus macaques, DEF201 beginning 1 day postinfection plus ZMAb beginning 4 days postinfection protected 50% of animals. Next steps include ongoing safety and toxicology studies for ZMAb and clinical testing of ZMAb and DEF201 by Defyrus Inc.</p> <p>SciBX 6(45); doi:10.1038/scibx.2013.1293 Published online Nov. 21, 2013</p>	MAbs for Ebola and use of interferon to treat infections patented; ZMAb licensed exclusively to Defyrus; DEF201 available for licensing for filovirus indications	<p>Qiu, X. <i>et al. Sci. Transl. Med.</i>; published online Oct. 16, 2013; doi:10.1126/scitranslmed.3006605</p> <p>Contact: Gary P. Kobinger, Public Health Agency of Canada, Winnipeg, Manitoba, Canada e-mail: gary.kobinger@phac-aspc.gc.ca</p>